Atypical antipsychotics—the cornerstone of schizophrenia treatment—are available as oral and long-acting depot formulations in the United States. Many of the oral atypical antipsychotic therapies used to treat the symptoms of schizophrenia are generically available, potentially creating barriers to access for branded oral agents (e.g., Sunovion’s Latuda, Otsuka/Lundbeck’s Rexulti, Allergan’s Vraylar). Newer depot formulations of atypical antipsychotics (e.g., Alkermes’s Aristada, Janssen’s Invega Trinza) offer the possibility of better patient compliance, although access to these therapies also may be restricted due to their high cost relative to other agents. With a wide variety of antipsychotic therapy options available, novel oral schizophrenia therapies will be entering a crowded and highly genericized market and may face reimbursement difficulties.
Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.